Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant n… Read more
Black Diamond Therapeutics Inc (BDTX) - Net Assets
Latest net assets as of September 2025: $126.15 Million USD
Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) has net assets worth $126.15 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($157.73 Million) and total liabilities ($31.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $126.15 Million |
| % of Total Assets | 79.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | -72.94% |
| 10-Year Change | N/A |
| Growth Volatility | 16.28 |
Black Diamond Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Black Diamond Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Black Diamond Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Black Diamond Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $83.28 Million | -28.66% |
| 2023-12-31 | $116.74 Million | +0.90% |
| 2022-12-31 | $115.69 Million | -40.94% |
| 2021-12-31 | $195.90 Million | -36.35% |
| 2020-12-31 | $307.76 Million | +752.62% |
| 2019-12-31 | $-47.16 Million | -203.42% |
| 2018-12-31 | $-15.54 Million | -132.84% |
| 2017-12-31 | $-6.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Black Diamond Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48032600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.01% |
| Other Comprehensive Income | $24.00K | 0.03% |
| Other Components | $570.36 Million | 684.83% |
| Total Equity | $83.28 Million | 100.00% |
Black Diamond Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Black Diamond Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BankFinancial Corporation
NASDAQ:BFIN
|
$102.49 Million |
|
Zhejiang Sunrise Garment Group Co Ltd
SHG:605138
|
$102.52 Million |
|
Global Water Resources Inc
NASDAQ:GWRS
|
$102.59 Million |
|
Bonduelle SAS
LSE:0N75
|
$102.67 Million |
|
Major-Power Technology Co., Ltd.
TWO:6720
|
$102.44 Million |
|
EKF DIAGNOST.HLDGS.LS-01
F:LYF
|
$102.41 Million |
|
Kofola CeskoSlovensko as
PR:KOFOL
|
$102.40 Million |
|
GTC
F:G91
|
$102.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Black Diamond Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 116,736,000 to 83,285,000, a change of -33,451,000 (-28.7%).
- Net loss of 69,676,000 reduced equity.
- New share issuances of 24,494,000 increased equity.
- Other comprehensive income increased equity by 51,000.
- Other factors increased equity by 11,680,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-69.68 Million | -83.66% |
| Share Issuances | $24.49 Million | +29.41% |
| Other Comprehensive Income | $51.00K | +0.06% |
| Other Changes | $11.68 Million | +14.02% |
| Total Change | $- | -28.66% |
Book Value vs Market Value Analysis
This analysis compares Black Diamond Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.93 | $2.23 | x |
| 2018-12-31 | $-1.11 | $2.23 | x |
| 2019-12-31 | $-1.31 | $2.23 | x |
| 2020-12-31 | $9.35 | $2.23 | x |
| 2021-12-31 | $5.41 | $2.23 | x |
| 2022-12-31 | $3.19 | $2.23 | x |
| 2023-12-31 | $2.66 | $2.23 | x |
| 2024-12-31 | $1.51 | $2.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Black Diamond Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -83.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.47x
- Recent ROE (-83.66%) is below the historical average (-39.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.93 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.38 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.54 Million |
| 2020 | -21.85% | 0.00% | 0.00x | 1.07x | $-98.03 Million |
| 2021 | -64.11% | 0.00% | 0.00x | 1.26x | $-145.19 Million |
| 2022 | -78.80% | 0.00% | 0.00x | 1.35x | $-102.74 Million |
| 2023 | -70.62% | 0.00% | 0.00x | 1.36x | $-94.12 Million |
| 2024 | -83.66% | 0.00% | 0.00x | 1.47x | $-78.00 Million |
Industry Comparison
This section compares Black Diamond Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Black Diamond Therapeutics Inc (BDTX) | $126.15 Million | 0.00% | 0.25x | $102.46 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |